Heart Transplantation, Elevated Resting Heart Rate Clinical Trial
Official title:
A Phase 3, Open-label, Multicenter Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients With Elevated Resting Heart Rate
The hypothesis is that the treatment with ivabradine will increase pVO2 after 16 weeks of treatment compared to baseline in the heart transplant recipient population with elevated resting HR.
The primary goal of this study is to assess the impact of ivabradine on cardiopulmonary
exercise capacity in heart transplant recipients with elevated resting heart rate (HR).
Exercise capacity will be assessed by the determination of the peak oxygen consumption (pVO2)
during standard cardiopulmonary exercise test before and after the treatment period with
ivabradine. The secondary goal is to determine HR reduction with ivabradine in the patient
population.
;